UNDISCLOSED Exclusive Financial Advisor & Exclusive Placement Agent Merger with Inmagene Biopharmaceuticals and Private Placement Financing Pending
Up to $950 Million Financial Advisor Sale of FYARRO® to Kaken Pharmaceutical and In-Licensing of Novel ADC Portfolio from WuXi Biologics December 2024